Century Therapeutics Inc. (IPSC) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Century Therapeutics Inc. (NASDAQ: IPSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $1.47 (+0.69% 1D, market cap $266.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IPSC ranks #1000 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPSC carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -14.1%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $257.6M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M). Among the 5-stock peer group, IPSC leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
Per IPSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850119), Century Therapeutics Inc. generated $109.2M in revenue (+1556.8% YoY), -$9.6M in net income, and -$104.7M in free cash flow against $223.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 44.9 (NEUTRAL RANGE)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IPSC currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.71) and Max Pain ($1.54) forces dealer call-delta covering toward $3.19.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Century Therapeutics Inc. (IPSC) advanced +0.69% to $1.47, trading at 40% of its 52-week range ($0.44 – $3.04). Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IPSC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IPSC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Century Therapeutics Inc. (IPSC) ranks #1000 by composite RQD confidence (18/100, grade E) and #531 by equity capitalization ($266.2M). Within this direct 5-issuer industry benchmark cohort, IPSC leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with IPSC at 18/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IPSC
ACTIVE
Century Therapeutics Inc. | E | 18/100 | — | — | -14.1% | +0.69% | $266.2M | Benchmark Subject |
| LXEO Lexeo Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +2.61% | $257.6M | /lxeo-vs-ipsc → |
| CABA Cabaletta Bio Inc. | E | 33/100 | — | — | -35.0% | -4.73% | $256.0M | /caba-vs-ipsc → |
| LCTX Lineage Cell Therapeutics Inc. | E | 20/100 | — | — | -35.0% | -2.91% | $252.9M | /lctx-vs-ipsc → |
| FATE Fate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -4.15% | $249.2M | /fate-vs-ipsc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Century Therapeutics Inc. (IPSC) reported GAAP revenue of $109.2M (+1556.8% vs. FY2024 revenue of $6.6M , and +4784.3% cumulative change since FY2023) , GAAP net income of -$9.6M, operating cash flow of -$103.9M, and free cash flow of -$104.7M (+5.0% YoY). On the balance sheet, IPSC closed FY2025 with $223.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $109.2M | -$9.6M | -$103.9M | -$104.7M | $223.7M | — |
| FY2024 (FY) | 2024-12-31 | $6.6M | -$126.6M | -$110.1M | -$110.3M | $353.2M | — |
| FY2023 (FY) | 2023-12-31 | $2.2M | -$136.7M | -$88.3M | -$88.3M | — | — |
As of 2026-11-03, Century Therapeutics Inc. (NASDAQ: IPSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $1.47 (+0.69% 1D, market cap $266.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IPSC ranks #1000 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPSC carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -14.1%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $257.6M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M). Among the 5-stock peer group, IPSC leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
Per IPSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850119), Century Therapeutics Inc. generated $109.2M in revenue (+1556.8% YoY), -$9.6M in net income, and -$104.7M in free cash flow against $223.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IPSC last traded at $1.47 (+0.69% on volume of 951,161 shares), positioning the stock -14.04% below its 50-day simple moving average ($1.71) and -29.67% below its 200-day simple moving average ($2.09). Across its 52-week range of $0.44 to $3.04, IPSC sits at the 39.6% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.29 to $1.65).
Why IPSC Stock advanced +0.69% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, IPSC scores 18 out of 100, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 0 out of 20, reflecting ROIC of -14.1% and FCF yield of 0%. The Whale 13F Flow pillar scores 4 out of 20, reflecting institutional accumulation and options positioning. The Insider Conviction pillar scores 3 out of 20, reflecting SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 6 out of 20, reflecting a beta of 1.0 and sector sensitivity. The Forensic Balance Sheet pillar scores 5 out of 20, reflecting an Altman Z-Score of 0.2, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5. For a prospective investor, the rating's weakest elements are cash generation and balance sheet strength, which are the pillars most directly tied to downside protection. Upside drivers, if any, are not identified as strengths in the rating itself; the stronger pillars (whale flow, insider flow) are still scored low. Valuation cannot be framed against earnings because P/E and EPS are not available in source data. Any upside thesis must rest on catalysts outside the rated fundamentals, and the source data does not quantify those.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $109.2M | $-17.3M | $-9.6M | N/A | $-104.7M | $61.9M | N/A |
| FY 2024 | $6.6M | $-138.1M | $-126.6M | N/A | $-110.3M | $58.4M | N/A |
| FY 2023 | $2.2M | $-146.5M | $-136.7M | N/A | $-88.3M | N/A | N/A |
Per the SEC financials, operating margin is -15.8%, net margin is -8.8%, and gross margin is 0%. ROIC is -14.1%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Reported FY 2025 revenue is well above FY 2024 and FY 2023, but operating and net losses remain negative in every period shown.
Per the recent news feed, the headlines are predominantly market-wire items (Yahoo! Finance Canada, Yahoo Finance Australia, TradingView) with no detailed event content in the summaries. The most specific item is that Century Therapeutics plans to attend the 2026 Jefferies Global Healthcare Conference in London. Other items are seasonal return charts and an earnings-estimate headline for Q3'26 showing a revenue estimate of 0 USD. Risk watch items include the negative cash flow and operating losses in the financials, and the Q3'26 revenue estimate of 0 USD. Per the Butterfly Supply-Chain Graph, the supply-chain status is NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Century Therapeutics Inc. (IPSC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Welcome to the IPSC (Century Therapeutics Inc.) Roar Pit. Current RQD Composite is 18/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on IPSC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Century Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on IPSC, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.46 (52-wk range $0.44 - $3.04), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).